USPTO serial 88356940
EMPOWER YOURSELF
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- BEN, LINDSEY HEATHER
- Law office
- TMEG LAW OFFICE 108 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with EMPOWER YOURSELF?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Burlington, Ontario, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nicole K. McLaughlin
Nicole K. McLaughlin DUANE MORRIS LLP30 S. 17TH ST.PHILADELPHIA, PA 19103-4196UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen, naproxen sodium, acetaminophen, cold, sore throat and cough medications, guaifenesin, liquid cough medicines with dextromethorphan, decongestant nasal sprays, pseudoephedrine, phenylephrine, allergy medications, antihistamine pills and liquids, diphenhydramine, chlorpheniramine, brompheniramine, loratadine, fexofenadine, cetirizine, stomach upset medications, antidiarrhea medicines, loperamide, bismuth, nausea and vomiting, motion sickness, dimenhydrinate; cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis for medical purposes; cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis for treating, reducing or improving symptoms of various conditions, namely, pain, anxiety, depression, cancer, acne, skin conditions, neuroprotection, cardiovascular health, arthritis, inflammation, autoimmune conditions, epileptic seizures, nausea, appetite, inflammatory bowel disease, and insomnia; cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis for medical purposes in sublingual doses and mucous membrane doses; skin creams, ointments, tablets, capsules, gummies, suppositories, skin patches, extended release tablets and liquids for therapeutic purposes containing cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; herbal supplements containing cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; Liquid nutritional supplements containing cannabidiol (CBD) which is synthetically derived with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis for treating, reducing or improving symptoms of various conditions, namely, pain, anxiety, depression, cancer, acne, skin conditions, neuroprotection, cardiovascular health, arthritis, inflammation, autoimmune conditions, epileptic seizures, nausea, appetite, inflammatory bowel disease, and insomnia | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 4, 2023 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 4, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 4, 2023 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Apr 12, 2023 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Apr 12, 2023 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jan 20, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 20, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 20, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 22, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 22, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 20, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 20, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 20, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 20, 2022 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jul 28, 2022 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jul 28, 2022 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jul 28, 2022 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jul 18, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jan 11, 2022 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jan 11, 2022 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jan 11, 2022 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jan 11, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 11, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 11, 2022 | ALIE | ASSIGNED TO LIE | — |
| Jan 7, 2022 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jul 9, 2021 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jul 9, 2021 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jul 9, 2021 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jul 8, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Aug 12, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Aug 12, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Aug 12, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 21, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 21, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 21, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 21, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 14, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 15, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 11, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 29, 2019 | NWAP | NEW APPLICATION ENTERED | — |